Inhibition/NN
of/IN
HIV-1/NN
replication/NN
by/IN
combination/NN
of/IN
a/DT
novel/JJ
inhibitor/NN
of/IN
TNF-alpha/NN
with/IN
AZT/NN
./.

The/DT
small/JJ
molecule/NN
S9a/NN
was/VBD
derived/VBN
from/IN
an/DT
established/JJ
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF-alpha/NN
)/)
inhibitor/NN
(/(
Canventol/NN
)/)
by/IN
replacement/NN
of/IN
the/DT
isopropylidine/NN
group/NN
with/IN
a/DT
phenyl/NN
ring/NN
./.
=====
S9a/NN
at/IN
10/CD
to/TO
100/CD
nM/NN
inhibited/VBD
HIV/NN
production/NN
as/RB
potently/RB
as/IN
3'-azido-3'-deoxythymidine/NN
(/(
AZT/NN
)/)
,/,
an/DT
inhibitor/NN
of/IN
viral/JJ
reverse/JJ
transcriptase/NN
./.
=====
Furthermore/RB
,/,
S9a/NN
and/CC
AZT/NN
in/IN
combination/NN
,/,
at/IN
noncytoxic/JJ
concentrations/NNS
strongly/RB
inhibited/VBD
HIV-1/NN
replication/NN
that/WDT
was/VBD
more/RBR
than/IN
additive/JJ
and/CC
substantially/RB
prolonged/VBD
the/DT
appearance/NN
of/IN
virus/NN
both/CC
in/IN
acutely/RB
infected/JJ
CD4+/JJ
lymphocytes/NNS
(/(
SupT/NN
)/)
in/IN
culture/NN
and/CC
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMCs/NNS
)/)
infected/VBN
with/IN
a/DT
primary/JJ
HIV-1/NN
isolate/NN
./.
=====
S9a/NN
inhibited/VBD
TNF-alpha/NN
promoter-driven/JJ
reporter/NN
gene/NN
activity/NN
./.
=====
It/PRP
was/VBD
proposed/VBN
that/IN
the/DT
mechanism/NN
of/IN
antiviral/JJ
action/NN
of/IN
S9a/NN
was/VBD
on/IN
the/DT
host/NN
cell/NN
,/,
by/IN
blocking/VBG
TNF-alpha/NN
transcription/NN
via/IN
a/DT
Tat-induced/JJ
tar-independent/JJ
loop/NN
,/,
which/WDT
decreases/VBZ
downstream/JJ
NF-kappaB/NN
activation/NN
of/IN
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
./.
=====
S9a/NN
was/VBD
superior/JJ
to/TO
the/DT
first/JJ
generation/NN
compound/JJ
Canventol/NN
,/,
which/WDT
was/VBD
superior/JJ
to/TO
the/DT
natural/JJ
compound/NN
sarcophytol/NN
A/NN
,/,
demonstrating/VBG
that/IN
further/JJ
structure-based/JJ
enhancement/NN
of/IN
potency/NN
of/IN
these/DT
compounds/NNS
is/VBZ
feasible/JJ
./.
=====
This/DT
study/NN
suggests/VBZ
a/DT
therapeutic/JJ
approach/NN
against/IN
AIDS/NN
by/IN
application/NN
of/IN
two/CD
drugs/NNS
,/,
one/CD
against/IN
a/DT
cellular/JJ
and/CC
the/DT
other/JJ
a/DT
viral/JJ
target/NN
,/,
which/WDT
may/MD
provide/VB
an/DT
approach/NN
to/TO
the/DT
problem/NN
of/IN
frequent/JJ
emergence/NN
of/IN
resistant/JJ
variants/NNS
to/TO
combinations/NNS
of/IN
drugs/NNS
that/WDT
target/VBP
only/RB
HIV/NN
genes/NNS
./.